Nathalie Stock

Vemurafenib-Induced Eccrine Squamous Syringometaplasia

We report herein a patient treated with vemurafenib for a stage IV melanoma who developed an eruption related to eccrine squamous syringometaplasia (ESS). This entity is a well-described side effect of cytostatic therapies used for malignant neoplasia and is clinically characterized by a symmetric cutaneous eruption composed of papules and vesicles preferentially located on fold and intertriginous areas. It is histologically defined by a squamous metaplasia of eccrine ductal epithelium. ESS represents another skin eruption to be added to the list of cutaneous adverse events associated with vemurafenib, a selective BRAF inhibitor used to treat patients with metastatic melanoma harboring the V600E mutation. The discussion focuses on the pathogenesis of ESS secondary to vemurafenib and on alternative diagnoses.

Réticulohistiocytose multicentrique: À propos d’un cas avec atteinte systémique

Resume La reticulohistiocytose multicentrique (RHM) est une histiocytose non langherhansienne (HNL) rare, a symptomatologie cutaneo-articulaire, pouvant toucher tous les organes. Elle peut s’associer a un cancer sous-jacent (environ 25 % des cas) [1] ou a une pathologie auto-immune [2,3]. L’examen anatomopathologique met en evidence un infiltrat nodulaire histiocytaire et giganto-cellulaire, a cytoplasme en verre depoli, PAS positif. Ces cellules sont CD68 positives et CD1a et PS100 negatives. Il n’est pas observe de granules de Birbeck en microscopie electronique. Nous rapportons le cas d’une patiente de 39 ans souffrant d’une RHM a manifestations cutanees, articulaires, musculaires et ORL.

Étude de l’expression des kinases Aurora dans le carcinome à cellules rénales ☆

OBJECTIVES The Aurora kinase family plays a crucial role in the regulation of mitosis. Over-expression of Aurora A and B has been reported in many malignant tumors. The objective of this study was to analyze the expression of Aurora A and B in renal cell carcinoma (RCC) and its correlation with usual clinical and pathological parameters. METHODS In a retrospective study, have been studied the tumoral samples of 40 consecutive patients who had been operated between 2003 and 2006 for a renal tumor. RNA was extracted from frozen corresponding tumoral samples. Thirty-one samples were retained based on RNA quality. RT-PCR was done on each of these samples to assess the expression of Aurora A and B genes. Statistical analysis was performed using Chi-square test to compare Aurora A and B levels. RESULTS Median age was 65 years (35-82). Seven (22%) patients had nodal invasion and eight (26%) had distant metastases. Most of the tumors (74%) were grade 3 or 4. Eighteen patients (58%) had clear cell cancer histology, 12 (39%) had papillary histology, and one a Bellini type tumor. Aurora A overexpression was associated with lymph node invasion (p=0.001). Aurora B over-expression was associated with both nodal involvement (p=0.02) and histologic subtype (significantly over-expressed in clear cell tumors; p=0.001). CONCLUSIONS Aurora A and B were differentially over-expressed in clear cell RCC and primary tumors of patients with lymph node involvement.

Article originalÉtude de l’expression des kinases Aurora dans le carcinome à cellules rénalesStudy of the expression of Aurora kinases in renal cell carcinoma☆

OBJECTIVES The Aurora kinase family plays a crucial role in the regulation of mitosis. Over-expression of Aurora A and B has been reported in many malignant tumors. The objective of this study was to analyze the expression of Aurora A and B in renal cell carcinoma (RCC) and its correlation with usual clinical and pathological parameters. METHODS In a retrospective study, have been studied the tumoral samples of 40 consecutive patients who had been operated between 2003 and 2006 for a renal tumor. RNA was extracted from frozen corresponding tumoral samples. Thirty-one samples were retained based on RNA quality. RT-PCR was done on each of these samples to assess the expression of Aurora A and B genes. Statistical analysis was performed using Chi-square test to compare Aurora A and B levels. RESULTS Median age was 65 years (35-82). Seven (22%) patients had nodal invasion and eight (26%) had distant metastases. Most of the tumors (74%) were grade 3 or 4. Eighteen patients (58%) had clear cell cancer histology, 12 (39%) had papillary histology, and one a Bellini type tumor. Aurora A overexpression was associated with lymph node invasion (p=0.001). Aurora B over-expression was associated with both nodal involvement (p=0.02) and histologic subtype (significantly over-expressed in clear cell tumors; p=0.001). CONCLUSIONS Aurora A and B were differentially over-expressed in clear cell RCC and primary tumors of patients with lymph node involvement.

Étude de l'expression des kinases Aurora dans le carcinome à cellules rénales. [Study of the expression of Aurora kinases in renal cell carcinoma].

OBJECTIVES The Aurora kinase family plays a crucial role in the regulation of mitosis. Over-expression of Aurora A and B has been reported in many malignant tumors. The objective of this study was to analyze the expression of Aurora A and B in renal cell carcinoma (RCC) and its correlation with usual clinical and pathological parameters. METHODS In a retrospective study, have been studied the tumoral samples of 40 consecutive patients who had been operated between 2003 and 2006 for a renal tumor. RNA was extracted from frozen corresponding tumoral samples. Thirty-one samples were retained based on RNA quality. RT-PCR was done on each of these samples to assess the expression of Aurora A and B genes. Statistical analysis was performed using Chi-square test to compare Aurora A and B levels. RESULTS Median age was 65 years (35-82). Seven (22%) patients had nodal invasion and eight (26%) had distant metastases. Most of the tumors (74%) were grade 3 or 4. Eighteen patients (58%) had clear cell cancer histology, 12 (39%) had papillary histology, and one a Bellini type tumor. Aurora A overexpression was associated with lymph node invasion (p=0.001). Aurora B over-expression was associated with both nodal involvement (p=0.02) and histologic subtype (significantly over-expressed in clear cell tumors; p=0.001). CONCLUSIONS Aurora A and B were differentially over-expressed in clear cell RCC and primary tumors of patients with lymph node involvement.